InduPro
Facts
- HQ
- Seattle
- Sectors
- Biotech, Oncology, Autoimmune
- Founded
- 2022
- Type
- Corporation Seattle business license
- Registered name
- InduPro Inc Seattle business license
- Stage
- Series B
InduPro raises $77M Series B, doses first patient in Phase 1 trial of IDP-001 targeting tumor protein pairs
InduPro raised $77 million in Series B financing and has dosed the first patient in a Phase 1 trial of IDP-001, an antibody-drug conjugate that uses the company’s ARRIS platform to target cancer cells by bringing two surface proteins together.
InduPro raises $77M Series B as it doses first patient in Phase 1 lung cancer trial
Seattle- and Cambridge-based biotech InduPro raised $77 million in a Series B to advance its oncology protein-therapeutics pipeline and is dosing the first patient in a Phase 1 trial targeting lung cancer and other solid tumors.
InduPro Raises $77M Series B Led by The Column Group and Doses First Patient in Phase 1 Trial of IDP-001
InduPro closed a $77 million Series B financing led by The Column Group and dosed the first patient in a Phase 1 trial of IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumor-associated proximity antigen for advanced squamous NSCLC and other solid tumors.
People
-
Prakash Raman Executive, Chief Executive Officer
